Stocks Amgen Inc

More

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 38 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 37 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • *Biogen to market biosimilar etanercept in Europe. LONDON, Nov 20- A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators. Worldwide sales of Amgen's Enbrel, which is marketed outside North America by...

  • LONDON, Nov 18- Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their...

  • LONDON, Nov 18- Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their...

  • ZURICH, Nov 18- The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's submission for approval of a biosimilar version of U.S.-based Amgen's Neulasta drug that fights infections in cancer patients, the Swiss group said on Wednesday. Amgen's third-quarter results last month showed sales of Neulasta up 6 percent to $1.26 billion, topping...

  • *Denmark's Genmab scores important win with new cancer drug. Shares in Genmab, already up 130 percent this year, leapt a further 12 percent on news that the drug, which was licensed to Johnson& Johnson in 2012, had won early U.S. approval, lifting Genmab's market value to around $7 billion. Still, with several analysts forecasting peak annual sales for Darzalex of $5...

  • Nov 17- Shares in Genmab jumped 11 percent on Tuesday after U.S. regulators approved an experimental blood cancer drug that the Danish biotech company licensed in 2012 to Johnson& Johnson. The U.S. Food and Drug Administration said late on Monday it had approved Darzalex for patients who had already undergone at least three prior standard treatments for...

  • Top strategist: Here's why chart analysis works Friday, 13 Nov 2015 | 11:06 AM ET
    Jeff DeGraaf

    Top chart analyst Jeff deGraaf explains why technical analysis should be a key part of your investing process.

  • Pro Talks: Top chart analyst says market top near Thursday, 12 Nov 2015 | 12:14 PM ET
    Jeff DeGraaf

    Top chart analyst Jeff deGraaf answers investment questions from CNBC Pro subscribers and explains why a market top could be forming.

  • ORLANDO, Nov 11- An experimental cholesterol fighter being developed by Alnylam Pharmaceuticals and The Medicines Co slashed levels of bad LDL cholesterol and remained effective for six months, according to data from a small, early stage study. The drug, called ALN-PCSsc, cut LDL by more than 50 percent in the 69- subject study presented at the American Heart...

  • The American Heart Association is holding its annual scientific sessions in Orlando, Florida from Nov 7 to 11, at which the latest clinical trials and research in heart care are being presented for thousands of cardiologists and researchers, including a large government-sponsored study on the benefits of more intensive blood pressure lowering in patients...

  • BOSTON, Nov 2- Daniel Loeb's Third Point hedge fund now holds more bets on stock price declines than gains, the billionaire told investors in a letter seen by Reuters on Monday, making him one of the first hedge fund managers to outline a new strategy following a turbulent third quarter. The biggest losers during the quarter include SunEdison, Dow Chemical Co.,...

  • Early movers: AET, TWC, MRO, MGM, SHW & more Thursday, 29 Oct 2015 | 7:56 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • After-hours buzz: GPRO, PYPL, BWLD, YELP & more Wednesday, 28 Oct 2015 | 5:43 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Take a look at some of Wednesday's after-hours buzz: GPRO, PYPL, BWLD, YELP & more.

  • Amgen stock gets boost from earnings beat Wednesday, 28 Oct 2015 | 4:02 PM ET
    Amgen

    Shares of Amgen popped nearly 2 percent in after-hours trade after the biotech company beat on its third-quarter earnings.

  • Amgen's big beat & raise Wednesday, 28 Oct 2015 | 4:01 PM ET
    Amgen's big beat & raise

    Amgen is reporting EPS of $2.72 adjusted, on revenue of $5.72 billion, with CNBC's Meg Tirrell. The company raised its full-year earnings forecast.

  • *Fed statement scheduled for 2 p.m. ET. Oct 28- U.S. stocks were higher on Wednesday, boosted by gains in Apple and a sharp bounce in energy stocks, ahead of the Federal Reserve's statement on interest rates. The market is likely to remain calm until after the Fed's announcement, said Jeff Powell, managing partner of Polaris Wealth Advisors.

  • Oct 28- Wall Street was set to open higher on Wednesday as investors await the Federal Reserve's latest policy statement, while Apple's strong results allayed some concerns about its business in China. Apple sold 48 million iPhones in the quarter and reported a near doubling of revenue from China. The issues they talked about in September are still there, "said...

  • All eyes on Fed; Apple gives Wall Street a boost Wednesday, 28 Oct 2015 | 8:37 AM ET
    A trader works on the floor of the New York Stock Exchange while Federal Reserve Chairwoman Janet Yellen explains why the Federal Reserve chose not raise interest rates on September 17, 2015 in New York.

    U.S. stock index futures pointed to a higher open on Wednesday ahead of a statement from the Fed this afternoon and more earnings.